BioSpace News Archive

According to NASDAQ, SPACs – Special Purpose Acquisition Companies – now make up more than a third of all IPOs.

Tryp and Dr. Miller have begun designing a Phase 2a open-label, exploratory clinical study utilizing TRP-8802 in patients suffering from rare and orphan over-eating disorders.

Bristol Myers Squibb and Exelixis announced new analysis from the Phase III CheckMate -9ER clinical trial.

Lonza has been in the process of separating LSI into a standalone unit since 2019.

ZYESAMI is intended to block the replication of SARS-CoV-2 in the ATII cell, as well as cytokine synthesis, thereby relieving respiratory distress. It is the only treatment in development that targets these ATII cells, and if approved, would be the first drug on the market for COVID-19 patients critically ill with respiratory failure.

Acasti Pharma Inc. announced its operating and financial results for the third quarter of fiscal 2021 ended December 31, 2020.

Lannett and HEC to Co-develop Insulin Aspart; Lannett Granted Exclusive US Commercialization Rights

Microbix Biosystems Inc., a life sciences innovator and exporter, is pleased to announce material first sales of its viral transport medium that supports Canadian RT-PCR testing for the virus causing COVID-19 disease.

- Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022

Eli Lilly and Company (NYSE: LLY) today announced the appointment of Anat Ashkenazi as senior vice president and chief financial officer. Ms. Ashkenazi, who most recently served in the role of senior vice president, controller and chief financial officer of Lilly Research Laboratories, succeeds Josh Smiley , who has resigned